Most Read

Eli Lilly and Company has announced that the US government is set to purchase additional doses of its neutralising antibody therapy, etesevimab, to treat Covid-19. Under the terms

The US Department of Health and Human Services (HHS) and the Department of Defense (DOD) have signed an agreement with Regeneron Pharmaceuticals to buy additional doses of the

Sanofi has completed the acquisition of messenger RNA (mRNA) therapies firm Translate Bio to expedite the use mRNA technology for the development of treatments and vaccines. The latest move

US-based biopharmaceutical firm AzurRx BioPharma has agreed to acquire clinical-stage biotechnology company First Wave Bio in a stock-and-cash deal valued at $229m. First Wave Bio is focussing on

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Amgen’s sotorasib (Lumakras) to treat patients with specific non-small cell lung cancer with KRAS G12C mutation. To be

EnGeneIC has started dosing in Phase I clinical trial of the world’s first nanocellular technology-based anti-Covid-19 vaccine in healthy adults. Referred to as EnGeneIC Dream Vector (EDV), the

The European Medicines Agency (EMA) has started evaluation of the data on a booster (third) dose for the Covid-19 vaccine, Comirnaty, developed by Pfizer and BioNTech. The move

Swedish Orphan Biovitrum (Sobi) has agreed a $8bn (SEK69.4bn) takeover offer from Advent International and Singapore’s wealth fund GIC. Sobi’s board of directors had unanimously recommended that shareholders

Merck and Ridgeback Biotherapeutics have initiated a Phase III clinical trial to evaluate investigational oral antiviral therapeutic molnupiravir to prevent Covid-19 infection. For the global MOVe-AHEAD study, individuals